Version history

{
  "session_id": "sess_hypdebate_h_0f025d94_20260426_164325",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "content": "\n\n## Expert Assessment: PLCG2 Allosteric Modulation for TREM2-Dependent Microglial Dysfunction\n\n### Druggability\n\nPLCG2 is a large enzyme (~1300 aa) with multiple regulatory domains (SH3-SH2-PLCγc), making allosteric targeting mechanistically feasible in principle. The existence of activating point mutations (e.g., P522R) validates that PLCG2 catalytic output can be therapeutically modulated without obliteration of the protein. However, a critical challenge is achieving selectivity over PLCG1 (~70% homology), which is broadly expressed and essential. The field lacks validated small-molecule allosteric modulators with sufficient selectivity and CNS penetration for microglial targeting. Developing such a compound de novo represents a high-risk, multi-year medicinal chemistry effort.\n\n### Competitive Landscape\n\nThis approach sits in a crowded but distinct niche adjacent to direct TREM2-targeting strategies. **Denali** (DNL-222/DNL919) and **Alector** (AL002, partnered with AbbVie) have TREM2 agonist antibodies in trials (NCT04931459, NCT05174702), offering more immediate competitive pressure with cleaner risk"
}